AIM ImmunoTech Inc. AIM
Set alert
0.15 USD -0.01 -4.04%
At close · Oct 30
0.16 +0.01 +3.56%
After hours · Oct 30, 7:50 PM ET
0.1545 Day range 0.1638
0.1545 52-week range 2.15
- YTD
- -85.95%
- 1 year
- -92.81%
- Open
- 0.164
- Prev close
- 0.161
- Mkt cap
- 6.16M
- Vol
- 386.13K
- Avg vol
- 4.70M
- EPS
- -2.98
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1545
- High
- 0.1638
- Forward P/E
- -0.48
- Beta
- -0.36
- Short ratio
- 1.63
- Inst. own
- 14.07%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.232
- 200-d avg
- 0.338
- 1y target
- 2.75
5Y chart
Events in this range
- Aug 15, 2023Earnings: -0.1; estimate 0; surprise —%
- Nov 14, 2023Earnings: -0.16; estimate 0; surprise —%
- Mar 29, 2024Earnings: -0.26; estimate 0; surprise —%
- May 16, 2024Earnings: -0.12; estimate 0; surprise —%
- Aug 14, 2024Earnings: -0.03; estimate 0; surprise —%
- Sep 3, 2024Rating: Ascendiant Capital · Buy → Buy
- Oct 22, 2024Rating: Maxim Group · Buy → Buy
- Nov 14, 2024Earnings: -0.06; estimate -0.1; surprise 40%
- Dec 10, 2024Rating: Ascendiant Capital · Buy → Buy
- Jan 9, 2026Split: 1001 for 1000
Signals (87)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Jun 8, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| RSI: Oversold | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Feb 16, 2026 | 8 months ago |
| RSI: Oversold | Feb 16, 2026 | 8 months ago |
| SMA: Bullish | Feb 9, 2026 | 8 months ago |
| RSI: Oversold | Jan 19, 2026 | 9 months ago |
| RSI: Oversold | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 20, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 18, 2025 | 1 year ago |
| RSI: Oversold | Aug 4, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jun 16, 2025 | 1 year ago |
| SMA: Bearish | Jun 2, 2025 | 1 year ago |
| SMA: Bullish | May 26, 2025 | 1 year ago |
| SMA: Bearish | May 12, 2025 | 1 year ago |
| SMA: Bullish | May 5, 2025 | 1 year ago |
| MACD: Buy Signal | May 5, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 10, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 10, 2025 | 1 year ago |
| RSI: Oversold | Feb 10, 2025 | 1 year ago |
| SMA: Bearish | Jan 13, 2025 | 1 year ago |
| SMA: Bullish | Dec 30, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 30, 2024 | 1 year ago |
| SMA: Bearish | Aug 26, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 24, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 10, 2024 | 2 years ago |
| SMA: Bullish | Jun 10, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 10, 2024 | 2 years ago |
| MACD: Sell Signal | May 20, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 22, 2024 | 2 years ago |
| SMA: Bullish | Mar 25, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 25, 2024 | 2 years ago |
| SMA: Bullish | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Dec 25, 2023 | 2 years ago |
| SMA: Bearish | Dec 11, 2023 | 2 years ago |
| SMA: Bullish | Dec 4, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| SMA: Bearish | Sep 25, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 18, 2023 | 3 years ago |
| SMA: Bearish | Aug 28, 2023 | 3 years ago |
| SMA: Bullish | Aug 14, 2023 | 3 years ago |
| SMA: Bearish | Aug 7, 2023 | 3 years ago |
| SMA: Bullish | Jun 26, 2023 | 3 years ago |
| SMA: Bullish | Jun 26, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bearish | Jun 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bullish | Jun 5, 2023 | 3 years ago |
| SMA: Bearish | May 29, 2023 | 3 years ago |
| SMA: Bullish | May 15, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bearish | May 8, 2023 | 3 years ago |
| SMA: Bullish | May 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Feb 13, 2023 | 3 years ago |
| SMA: Bullish | Feb 6, 2023 | 3 years ago |
| SMA: Bearish | Jan 23, 2023 | 3 years ago |
| SMA: Bullish | Jan 9, 2023 | 3 years ago |
| SMA: Bullish | Jan 2, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 2, 2023 | 3 years ago |
| MACD: Sell Signal | Nov 14, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 7, 2022 | 3 years ago |
| RSI: Oversold | Nov 7, 2022 | 3 years ago |
| RSI: Oversold | Oct 24, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 15, 2022 | 4 years ago |
| RSI: Oversold | Aug 15, 2022 | 4 years ago |
| MACD: Buy Signal | Aug 8, 2022 | 4 years ago |
| MACD: Sell Signal | Jul 11, 2022 | 4 years ago |
| RSI: Oversold | Jul 11, 2022 | 4 years ago |
| RSI: Oversold | Jun 27, 2022 | 4 years ago |
| RSI: Oversold | Jun 13, 2022 | 4 years ago |
| SMA: Bearish | May 9, 2022 | 4 years ago |
| SMA: Bullish | Mar 7, 2022 | 4 years ago |
Key statistics
- Market cap
- 12.44M
- Enterprise value
- 6.04M
- Trailing P/E
- 0.00
- Forward P/E
- -0.48
- PEG ratio
- 0.00
- Price / sales
- 61.88
- Price / book
- 1.01
- EPS (TTM)
- -0.47
- Beta
- -0.36
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 201.00K
- Revenue growth
- 19.00%
- Free cash flow
- -16.04M
- Total cash
- 10.06M
- Total debt
- 3.36M
- Return on equity
- -154.79%
- Shares outstanding
- 63.78M
- Short % of float
- 0.85%
- 50-day average
- 0.232
- 200-day average
- 0.338
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 2.75 +1679.9% upside
Now 0.1545
- Target (low)
- 1.00
- Target (mean)
- 2.75
- Target (high)
- 4.50
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy1
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.09.
Financials — quick view
AIM Revenue — quarterly 26.00K
AIM Net income — quarterly -3.79M
AIM EPS — quarterly -0.43
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.10 | -0.06 | +0.04 | +40.00% |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.03 | — | — |
| May 16, 2024 | Mar 1, 2024 | 0.00 | -0.12 | — | — |
| Mar 29, 2024 | Dec 1, 2023 | 0.00 | -0.26 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.16 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -0.10 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 22, 2024 | Maxim Group | main | Buy | Buy |
| Sep 3, 2024 | Ascendiant Capital | main | Buy | Buy |
| Oct 10, 2019 | Maxim Group | up | Hold | Buy |
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- aimimmuno.com
News
- AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
- AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
- AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
- Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace
- AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
- Ondine Biomedical pauses trading to raise fresh investment after positive phase III result
- 1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition
- 1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years
- Digitalbox eyes creator-led growth as it rides out Meta disruption
- AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Your note
Sign in to keep a note on AIM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| APPELROUTH STEWART L. | Director | Stock Award(Grant) | Dec 12, 2024 | 379,961 |
| BRYAN NANCY K | Director | Stock Award(Grant) | Dec 12, 2024 | 85,559 |
| EQUELS THOMAS K | Chief Executive Officer | Purchase | Dec 17, 2024 | 1,680,700 |
| MITCHELL WILLIAM M | Director | Sale | Dec 18, 2024 | 118,929 |
| RODINO PETER W III | Chief Operating Officer | Stock Award(Grant) | Aug 11, 2024 | 401,262 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 6.79% | 4,330,000 | 844.35K | Sep 29, 2024 |
| Vanguard Group Inc | 3.12% | 1,988,704 | 387.80K | Sep 29, 2024 |
| Blackrock Inc. | 1.09% | 698,267 | 136.16K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.73% | 464,016 | 90.48K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.72% | 457,767 | 89.26K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 0.38% | 243,208 | 47.42K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.06% | 1,311,599 | 255.76K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.97% | 620,229 | 120.94K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.48% | 303,016 | 59.09K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.11% | 71,505 | 13.94K | Oct 30, 2024 |
| Vanguard Institutional Index-Inst Total Stock Market Ind | 0.07% | 43,668 | 8.52K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.06% | 36,509 | 7.12K | Oct 30, 2024 |